← SWS Hemodialysis Care Co. Ltd. A overview

SWS Hemodialysis Care Co. Ltd. A vs DaVita HealthCare Partners: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

SWS Hemodialysis Care Co. Ltd. A (688410.CG)

Q3 202622 Jul – 28 Aug 2026

▲3▼1

Strong H1 profit and new product approvals offset major shareholder selling

H1 profit jumps 71% on higher sales and margins SWS reported first-half 2026 revenue up 29.8% to 464 million yuan and net profit up 71.46% to 94.37 million yuan. Higher sales of self-made blood purification consumables and better gross margin drove the gain, showing the core business is growing profitably.
This is the main positive force behind the stock, showing strong underlying business momentum.
New product approvals expand market access A subsidiary received a medical device registration certificate for single-use hemodialysis blood tubing and a change filing for continuous blood purification tubing. These approvals let SWS sell more products in hospitals, supporting future revenue growth.
New product approvals are a concrete growth driver that can lift future sales and investor confidence.
High dividend payout signals confidence and cash returns SWS plans to pay 2 yuan per 10 shares, a 94.83% payout of first-half profit. A high dividend returns cash to shareholders and signals management's confidence in steady earnings, which can attract income-focused investors.
The dividend is a new capital return event that supports the stock's appeal and shows financial health.
Major shareholder plans to sell up to 4.03% stake A major shareholder plans to cut its stake by up to 4.03%, worth about 200 million yuan, starting September 3. This is the third reduction plan in a year, which can pressure the stock price by increasing the number of shares for sale.
This is the main counterweight to the positive news, explaining why the stock may face selling pressure.

August 202622 Jul – 28 Aug 2026

▲3▼1

Strong H1 profit and new product approvals offset major shareholder selling

H1 profit jumps 71% on higher sales and margins SWS reported first-half 2026 revenue up 29.8% to 464 million yuan and net profit up 71.46% to 94.37 million yuan. Higher sales of self-made blood purification consumables and better gross margin drove the gain, showing the core business is growing profitably.
This is the main positive force behind the stock, showing strong underlying business momentum.
New product approvals expand market access A subsidiary received a medical device registration certificate for single-use hemodialysis blood tubing and a change filing for continuous blood purification tubing. These approvals let SWS sell more products in hospitals, supporting future revenue growth.
New product approvals are a concrete growth driver that can lift future sales and investor confidence.
High dividend payout signals confidence and cash returns SWS plans to pay 2 yuan per 10 shares, a 94.83% payout of first-half profit. A high dividend returns cash to shareholders and signals management's confidence in steady earnings, which can attract income-focused investors.
The dividend is a new capital return event that supports the stock's appeal and shows financial health.
Major shareholder plans to sell up to 4.03% stake A major shareholder plans to cut its stake by up to 4.03%, worth about 200 million yuan, starting September 3. This is the third reduction plan in a year, which can pressure the stock price by increasing the number of shares for sale.
This is the main counterweight to the positive news, explaining why the stock may face selling pressure.

Latest22 Jul – 28 Aug 2026

▲3▼1

Strong H1 profit and new product approvals offset major shareholder selling

H1 profit jumps 71% on higher sales and margins SWS reported first-half 2026 revenue up 29.8% to 464 million yuan and net profit up 71.46% to 94.37 million yuan. Higher sales of self-made blood purification consumables and better gross margin drove the gain, showing the core business is growing profitably.
This is the main positive force behind the stock, showing strong underlying business momentum.
New product approvals expand market access A subsidiary received a medical device registration certificate for single-use hemodialysis blood tubing and a change filing for continuous blood purification tubing. These approvals let SWS sell more products in hospitals, supporting future revenue growth.
New product approvals are a concrete growth driver that can lift future sales and investor confidence.
High dividend payout signals confidence and cash returns SWS plans to pay 2 yuan per 10 shares, a 94.83% payout of first-half profit. A high dividend returns cash to shareholders and signals management's confidence in steady earnings, which can attract income-focused investors.
The dividend is a new capital return event that supports the stock's appeal and shows financial health.
Major shareholder plans to sell up to 4.03% stake A major shareholder plans to cut its stake by up to 4.03%, worth about 200 million yuan, starting September 3. This is the third reduction plan in a year, which can pressure the stock price by increasing the number of shares for sale.
This is the main counterweight to the positive news, explaining why the stock may face selling pressure.

DaVita HealthCare Partners Inc (DVA)

Q3 202617 Jun – 7 Aug 2026

▲2▼2

DaVita's strong Q2 beat overshadowed by soft guidance and falling revenue per treatment

Integrated Kidney Care expansion drives growth DaVita is expanding its Integrated Kidney Care program beyond hospitals, with 62,600 patients in risk-based arrangements representing $5.4 billion in annual medical spend. This growing value-based care platform boosts demand and could improve margins through performance payments.
This is a new strategic growth driver that supports future earnings and offsets reimbursement pressure.
Raised 2026 guidance and share buybacks DaVita raised full-year 2026 guidance to adjusted operating income of $2.15-$2.25 billion and EPS of $14.10-$15.20, and repurchased 5 million shares through early May. This signals confidence and returns cash to shareholders, supporting the stock price.
Guidance raise and buybacks are direct positive catalysts for the stock.
Q2 revenue per treatment decline and lower cash Despite beating Q2 estimates, revenue per treatment fell $1.72 sequentially to $415.87, and cash declined to $771.8 million from $782.1 million. These operational pressures weighed on investor sentiment, contributing to a 7% share drop.
This explains the negative price reaction despite headline beats.
Full-year EPS guidance midpoint below consensus DaVita reaffirmed 2026 adjusted EPS guidance of $14.10-$15.20, with a midpoint of $14.65 below the $14.88 consensus. This disappointed investors and led to a 17% stock decline, as the market expected a raise.
This is the key reason for the sharp negative price move after earnings.

July 202617 Jun – 7 Aug 2026

▲2▼2

DaVita's strong Q2 beat overshadowed by soft guidance and falling revenue per treatment

Integrated Kidney Care expansion drives growth DaVita is expanding its Integrated Kidney Care program beyond hospitals, with 62,600 patients in risk-based arrangements representing $5.4 billion in annual medical spend. This growing value-based care platform boosts demand and could improve margins through performance payments.
This is a new strategic growth driver that supports future earnings and offsets reimbursement pressure.
Raised 2026 guidance and share buybacks DaVita raised full-year 2026 guidance to adjusted operating income of $2.15-$2.25 billion and EPS of $14.10-$15.20, and repurchased 5 million shares through early May. This signals confidence and returns cash to shareholders, supporting the stock price.
Guidance raise and buybacks are direct positive catalysts for the stock.
Q2 revenue per treatment decline and lower cash Despite beating Q2 estimates, revenue per treatment fell $1.72 sequentially to $415.87, and cash declined to $771.8 million from $782.1 million. These operational pressures weighed on investor sentiment, contributing to a 7% share drop.
This explains the negative price reaction despite headline beats.
Full-year EPS guidance midpoint below consensus DaVita reaffirmed 2026 adjusted EPS guidance of $14.10-$15.20, with a midpoint of $14.65 below the $14.88 consensus. This disappointed investors and led to a 17% stock decline, as the market expected a raise.
This is the key reason for the sharp negative price move after earnings.

Latest17 Jun – 7 Aug 2026

▲2▼2

DaVita's strong Q2 beat overshadowed by soft guidance and falling revenue per treatment

Integrated Kidney Care expansion drives growth DaVita is expanding its Integrated Kidney Care program beyond hospitals, with 62,600 patients in risk-based arrangements representing $5.4 billion in annual medical spend. This growing value-based care platform boosts demand and could improve margins through performance payments.
This is a new strategic growth driver that supports future earnings and offsets reimbursement pressure.
Raised 2026 guidance and share buybacks DaVita raised full-year 2026 guidance to adjusted operating income of $2.15-$2.25 billion and EPS of $14.10-$15.20, and repurchased 5 million shares through early May. This signals confidence and returns cash to shareholders, supporting the stock price.
Guidance raise and buybacks are direct positive catalysts for the stock.
Q2 revenue per treatment decline and lower cash Despite beating Q2 estimates, revenue per treatment fell $1.72 sequentially to $415.87, and cash declined to $771.8 million from $782.1 million. These operational pressures weighed on investor sentiment, contributing to a 7% share drop.
This explains the negative price reaction despite headline beats.
Full-year EPS guidance midpoint below consensus DaVita reaffirmed 2026 adjusted EPS guidance of $14.10-$15.20, with a midpoint of $14.65 below the $14.88 consensus. This disappointed investors and led to a 17% stock decline, as the market expected a raise.
This is the key reason for the sharp negative price move after earnings.